Centogene N.V.

General information
Centogene N.V.
Am Strande 7
18055 Rostock, Mecklenburg-Vorpommern
Germany

Contact person: Peter Bauer, Chief Genomic Officer
Company main phone: +49 (381) 80113400
Company main fax:  +49 (381) 80113401
Website:  https://www.centogene.com
Year founded:2006
Source of foundation:Independent foundation
No. of employees: Worldwide:  444
Corporate description / mission:
Centogene N.V. is a rare disease company focused on transforming clinical, genetic, and biochemical data into medical solutions for patients. The company provides the full spectrum of modern methods and technology for human genetics analysis. The company also active in research and is constantly developing new products for human genetics.
State of ownership: Publicly listed on stock exchange
Headquarters: HQ: Yes
IPO (year): 2019
Categorization
Sector:
  • Biotechnology - R&D Services
Subsector:
  • Analytical services
  • Bioinformatics
  • Diagnostic services
  • Genomics
Primary therapeutic areas:
  • Cardiovascular / cardiology
  • Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
  • Diseases of the ear / otology
  • Diseases of the eye / ophthalmology
  • Diseases of the nervous system / neurology
  • Endocrine, nutritional and metabolic diseases / endocrinology
  • Genitourinary system / Urology
  • Musculoskeletal system and connective tissue / Orthopedics
  • Neoplasms / cancer / oncology
  • Respiratory / pulmonology
  • Skin and subcutaneous tissue / dermatology
  • Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
Business model:
  • R&D
  • Service company
  • Supplier / Distributor
Customer segments:
  • Other
  • Consumers (mass market)
  • Hospitals
  • Physicians / doctors
Distribution:
  • Direct (own sales force)
Summary Products / Services / Technologies
Description of products:
Prenatal Testing
Newborn testing
Metabolic Testing
Hereditary Cancer Testing, etc.
Financing details
Fiscal year (end of) 2023
Revenues:USD 51.44M
R&D expenses:USD 11.00M
Cash:USD 20.68M
Total liabilities:USD 104.75M
No. of shares:29'000'100
Market cap. / valuation:USD 10.59M
X